CSL Dirección

Dirección controles de criterios 1/4

El CEO de CSL es Paul McKenzie , nombrado en Mar 2023, tiene una permanencia de 1.58 años. compensación anual total es $8.18M, compuesta por 23.1% salario y 76.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.006% de las acciones de la empresa, por valor de CHF4.68M. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 4 años, respectivamente.

Información clave

Paul McKenzie

Chief Executive Officer (CEO)

US$8.2m

Compensación total

Porcentaje del salario del CEO	23.1%
Permanencia del CEO	1.6yrs
Participación del CEO	0.006%
Permanencia media de la dirección	1.6yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul McKenzie en comparación con los beneficios de CSL?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	US$8m	US$2m	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Compensación vs. Mercado: La compensación total de Paul($USD8.18M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD4.76M).

Compensación vs. Ingresos: La compensación de Paul ha aumentado más de un 20% en el último año.

CEO

Paul McKenzie (58 yo)

1.6yrs

Permanencia

US$8,183,842

Compensación

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul McKenzie	MD, CEO & Executive Director	1.6yrs	US$8.18m	0.0056% CHF 4.7m
Joy Linton	Interim Executive Vice President of CSL Behring	less than a year	US$3.73m	0.0025% CHF 2.1m
Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)	1.3yrs	US$4.07m	0.00044% CHF 369.7k
John A. Levy	Interim Chief Financial Officer	less than a year	sin datos	sin datos
Chris Cooper	Head of Investor Relations	no data	sin datos	sin datos
Gregory Boss	Executive VP of Legal & General Counsel	15.8yrs	US$2.31m	sin datos
Roanne Parry	Chief Human Resources Officer	less than a year	sin datos	sin datos
Karen Etchberger	Executive Vice President of Quality & Business Services	14.5yrs	US$2.14m	sin datos
Jemimah Brennan	Head of Communications - Asia Pacific	no data	sin datos	sin datos
Andrew Nash	Senior Vice President of Research	no data	sin datos	sin datos
William Mezzanotte	Executive VP & Head of Research and Development	6yrs	US$2.14m	sin datos
Mark Hill	Chief Digital Information Officer & Executive VP	4yrs	sin datos	sin datos

1.6yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CSJ no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul McKenzie	MD, CEO & Executive Director	1.8yrs	US$8.18m	0.0056% CHF 4.7m
Megan Clark	Independent Non Executive Director	8.7yrs	US$242.44k	0.0011% CHF 915.8k
Alison Watkins	Independent Non-Executive Director	3.2yrs	US$240.56k	0.00077% CHF 647.0k
Carolyn Hewson	Independent Non-Executive Director	4.8yrs	US$237.09k	0.00047% CHF 394.9k
Brian McNamee	Independent Non-Executive Chairman	6.7yrs	US$604.85k	0.026% CHF 22.0m
Robert Cuthbertson	Non-Independent Non-Executive Director	6yrs	US$221.35k	0.015% CHF 12.3m
Duncan Maskell	Independent Non-Executive Director	3.2yrs	US$190.94k	0.00035% CHF 294.1k
Marie McDonald	Independent Non-Executive Director	11.2yrs	US$215.19k	0.00088% CHF 739.4k
Samantha Lewis	Independent Non-executive Director	less than a year	US$91.12k	0.00041% CHF 344.5k
Elaine Sorg	Independent Non-Executive Director	less than a year	sin datos	sin datos

4.0yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CSJ se considera experimentada (4 años de antigüedad promedio).

CSL Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

High number of new directors

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

New minor risk - Financial position

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

High number of new directors

CSL Limited Provides Financial Guidance for Fiscal 2022

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad